预约演示

更新于：2025-05-07

Sufentanil Citrate

枸橼酸舒芬太尼

更新于：2025-05-07

概要

基本信息

药物类型

小分子化药

别名

Sufentanil TDS (free base)、Sufentanil citrate (USP)、sufentanil

+ [14]

靶点

Opioid receptors

作用方式

激动剂

作用机制

Opioid receptors激动剂(阿片样受体激动剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Rising Pharmaceuticals, Inc.

Laboratoire Aguettant SAS

+ [1]

非在研机构

FGK Representative Service GmbH

Talphera, Inc.

Vertical Pharmaceuticals LLC

权益机构

Alora Pharmaceuticals LLC

The Brigham & Women's Hospital, Inc.

Talphera, Inc.

+ [5]

最高研发阶段批准上市

首次获批日期

美国 (1984-05-04),

麻醉阴道分娩过程

最高研发阶段(中国)批准上市

特殊审评优先审评 (中国)

登录后查看时间轴

结构/序列

分子式C28H38N2O9S

InChIKeyOJCZPLDERGDQRJ-UHFFFAOYSA-N

CAS号60561-17-3

查看全部结构式(2)

关联

126

项与枸橼酸舒芬太尼相关的临床试验

ChiCTR2500100164

/ Suspended临床1期IIT

Efficacy and Safety of Hydromorphone or Sufentanil Combined With Programmed Epidural Intermittent Administration of Ropivacaine for Labor Analgesia ---- a Randomized, Controlled, Double-blind, Non-inferiority Study - Efficacy and Safety of Hydromorphone or Sufentanil Combined With Programmed Epidural Intermittent Administration of Ropivacaine for Labor Analgesia ---- a Randomized, Controlled, Double-blind, Non-inferiority Study

开始日期2025-09-01

申办/合作机构-

NCT06917651

/ Recruiting临床3期IIT

Management of Moderate to Severe Monotraumatic Pain With Sublingual Sufentanil in an Emergency Situation.

Pain is a common reason for emergency department (ED) visits. However, studies suggest that emergency physicians may not always provide optimal analgesic treatment due to various factors, such as time constraints, demographic factors like gender and age, and concerns about opioid use. As a result, patients with moderate to severe pain often experience long delays before receiving analgesia and may even be discharged with unresolved pain or suboptimal treatment. Additionally, diagnostic procedures for patients with isolated trauma (e.g., clinical examinations, radiographs) can lead to variations in pain levels, making it difficult to assess the effectiveness of analgesia.
A commonly used treatment for moderate to severe pain is intravenous opioid administration. However, this approach requires longer wait times, complex titration, and significant resources (beds, nurses, equipment), which may be limited during peak hours. While oral opioids require fewer resources, their delayed onset and limited titratability restrict their use for severe pain.
The sublingual sufentanil tablet (30 mcg), delivered via a single-dose applicator, was developed for patients with moderate to severe pain in emergency or outpatient surgical settings. Its unique pharmacokinetic and pharmacodynamic properties could offer advantages in non-invasive acute pain management.
Sublingual sufentanil received market authorization in June 2018 for the treatment of moderate to severe acute pain in adults and is already used in many hospitals. However, further studies are needed to confirm its effectiveness and potential superiority in pain management.
The objective of this study is to evaluate the effectiveness of 30 mcg sublingual sufentanil in patients admitted for moderate to severe pain due to isolated trauma. This will be compared to the standard pain management protocol used in the Clermont-Ferrand emergency department, focusing on pain score variations using a numerical rating scale (0-10)

开始日期2025-04-22

申办/合作机构

Centre Hospitalier Universitaire de Clermont Ferrand

ChiCTR2500098772

/ Suspended临床4期IIT

Comparison of efficacy and safety of Afentanil, oxelidine fumarate, Sufentanil combined with etomidate and propofol in painless gastroscopy

开始日期2025-04-15

申办/合作机构-

100 项与枸橼酸舒芬太尼相关的临床结果

登录后查看更多信息

100 项与枸橼酸舒芬太尼相关的转化医学

登录后查看更多信息

100 项与枸橼酸舒芬太尼相关的专利（医药）

登录后查看更多信息

3,840

项与枸橼酸舒芬太尼相关的文献（医药）

2025-09-01·Talanta

SERS detection of analgesics in serum based on Ag nanocubes for perioperative monitoring

Article

作者: Ji, Yinghe ; Zhu, Zhuo ; Sun, Tingting ; Wang, Yunpeng ; Li, Yang ; Wu, Jing ; Qin, Lei ; Han, Lin

Prompt and personalized perioperative analgesia management relies on sensitive and convenient monitoring of analgesics. We report a strategy for sensitive and reproducible SERS detection of analgesics based on Ag nanocubes, which have abundant intragranular hot spots on sharp corners and interparticle hot spots between gaps. Both theoretical simulations and R6G detection experiments indicated that the enhancement factor of Ag nanocube SERS platform reach to 10⁶ level. Quantitative and reproducible determination capabilities of this platform for six different analgesics with LOD as low as 500 pg mL^-1 were verified. Pharmacokinetic experiment of fentanyl in rat serum samples by SERS detection within 4 h presented consistent results with the UHPLC-MS/MS method. Valid examples of SERS detection for single or multiple analgesics in clinical patients' serums further proved the feasibility of this platform for perioperative analgesic monitoring.

2025-06-01·Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy

A chemoinformatics study to prioritization of anticancer orally active lead compounds of pearl millet against adhesion G protein-coupled receptor

Article

作者: Shukla, Adarsh Kumar ; Neeru ; Kumar, Ashwani

Metastasis is the main cause of colon cancer deaths worldwide. However, due to the disease's complexity, understanding its spread and finding natural treatments remain major challenges. The study aimed to identify therapeutic compounds in pearl millet and test them on metastatic colon cancer cell lines. The study used LC-MS and FTIR spectroscopy to identify small compounds and their functional groups. Further, theoretical chemistry, computational techniques, and ADMET analysis were applied for virtual screening and evaluating the pharmacokinetics of potential bioactive candidates of pearl millet. The 55 compounds of pearl millet were identified through the LC-MS, whereas 37 compounds were reported in PubChem database. Out of these, 15 compounds were predicted as potential orally active leads of pearl millet. Adhesion G protein-coupled receptor F5 was found as a potential target of these lead candidates. Further, molecular docking exhibited Tosifen (-7.9 kcal/mol), Sufentanil (-6.4 kcal/mol), Pemirolast (-6.3 kcal/mol), and Levosimendan (-6.3 kcal/mol) have similar binding affinity to the antineoplastics against the targeted protein. The "root mean square fluctuations (RMSFs)" analysis and deformability graph validated the docked complexes. Additionally, a comparative cell lines study against colon adenocarcinoma highlights Pemirolast as a promising candidate, demonstrating better activity compared to standard antineoplastics. This computational study predicted potential anticancer compounds in pearl millet and recommended further investigation through in vitro and in vivo studies.

2025-06-01·Food Chemistry

High-throughput screening of new psychoactive substances and related compounds in food by UHPLC-Q/Orbitrap

Article

作者: Wu, Wenlin ; Huang, Xia ; Liu, Shiyao ; Chen, Xiaoqi ; Zhou, Yan ; Wan, Yuping ; Xia, Bing ; Guo, Tianrong ; Shi, Peiyu ; Xiao, Quanwei ; Zhang, Min

Currently, there is concern about food products to which new psychoactive substances (NPS) have been added illegally. However, rapid, high-sensitivity, and high-throughput screening methods for such harmful substances have not been reported yet. In this study, a high-throughput non-targeted screening strategy was developed based on UHPLC-Q/Orbitrap. First, optimized pretreatment methods for typical high-risk matrices were established. Second, an accurate, efficient, and scalable high resolution mass spectrometry database containing 206 NPS and related compounds was constructed. The fragmentation pathways of three different types of fentanyl-related compounds were then systematically investigated to enhance compound identification. Additionally, a non-targeted screening strategy was developed using warning ions derived from 24 fentanyl-related compounds, streamlining the identification of NPS. This strategy was applied to 100 food samples with possible illegal additives and demonstrated its effectiveness. In summary, this study provides robust technical support for regulatory authorities in combating the illegal addition of food products.

项与枸橼酸舒芬太尼相关的新闻（医药）

2025-04-18

·摩熵医药

71个首家过评品种！九典制药3个独家领跑

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。在国家药品集采常态化推进与仿制药质量升级的双重驱动下，药品一致性评价已成为推动仿制药质量提升、优化市场格局的关键举措，不仅关乎着药品的疗效与安全性，更深刻影响着企业的市场竞争力和行业的发展走向。新增71个药品首家过评！九典制药领跑据摩熵医药一致性评价数据库统计，截至2025年4月17日，2025年期间共有483个（共计1221个受理号）品种通过/视同通过（新注册分类仿制药获批上市）一致性评价，其中一致性评价过评品种数量为100个，视同通过一致性评价品种数量为413个。从治疗领域分布情况来看，在此期间过评的药品品种中，排名前三的分别为消化系统与代谢药物（占比16.02%）、系统用抗感染药物（占比14.2%）以及心血管系统药物（占比13.59%）。截图来源：摩熵医药一致性评价数据库从过评品种来看，（按通过/视同通过受理号数计）排名前三的药品分别为罗沙司他胶囊、乳果糖口服溶液以及注射用头孢唑肟钠。从过评企业来看，（按通过/视同通过品种数计）排名前三的企业分别是浙江赛默制药、四川科伦药业和石四药，过评的药品品种数量分别为22个、15个和12个。图片来源：摩熵医药一致性评价数据库2025年以来，首家过评品种达71个，其中60个为独家过评品种。其中，按通过/视同通过品种数计，九典制药以3个独家过评品种领跑，人福药业、江西科睿药业、齐鲁制药等6家企业各斩获2个，形成差异化竞争优势。首家过评意味着企业在仿制药质量和疗效上率先获得认可，不仅能享受政策红利（如优先采购、价格优势），还能在市场准入中占据主动。图片来源：摩熵医药一致性评价数据库麻醉镇痛领域领军企业——人福药业作为国内麻醉镇痛领域的领军企业，据摩熵医药数据统计，人福药业（宜昌+武汉）2025年以来已有8个品种获批生产并视同过评，包括琥珀酸地文拉法辛缓释片、盐酸他喷他多片（国内首仿）、塞来昔布胶囊、多巴丝肼片、奥卡西平口服混悬液、富马酸二甲酯肠溶胶囊、盐酸伐昔洛韦片、马来酸咪达唑仑片（首家过评）。其中，盐酸他喷他多片以仿制3类报产获批，是该产品首仿和首家过评企业，获批适应症为用于治疗成人患者需要使用阿片类药物治疗，且替代治疗不能充分缓解的急性疼痛。其最早由美国强生与德国格兰泰公司合作研发，作为一种创新的阿片类镇痛药物，其于2008年11月在美国首次获批上市，随后逐步进入国际市场。宜昌人福药业（人福医药核心子公司）长期专注于麻醉药品和精神类药物的研发，拥有丰富的产品线和技术积累。从具体产品市场占有率来看，其麻醉药市场中的阿芬太尼和氢吗啡酮市占率均为100%；枸橼酸舒芬太尼市占率由2014年的82.5%逐渐提高至2021年的98%，龙头地位持续强化；瑞芬太尼市占率始终保持近90%，纳布啡市占率超96%，芬太尼市占率始终维持在98%左右。人福医药研发管线治疗领域分布图片来源：摩熵医药全球药物研发数据库麻醉镇痛市场集中度高，行业数据显示，2023年人福医药在麻醉镇痛市场以25.9%的市占率排名第一，扬子江药业18.1%，恒瑞医药12.2%，恩华药业5.4%。由于恒瑞体量太大，细分市场景气度带来的边际改善不明显，精麻头部玩家主要有4家，包括人福医药、恩华药业、海思科、苑东生物，后两者是新贵，凭借差异化创新药策略，为行业注入新的增长动能。小结一致性评价不仅是药品质量的“试金石”，更是产业结构优化的“催化剂”。随着集采政策的常态化推进，通过一致性评价的品种将凭借质量与成本优势持续扩大市场份额，而独家过评、首仿品种的政策红利将进一步凸显创新与速度的战略价值。END本文为原创文章，转载请留言获取授权近期热门资源获取CGT产业现状与未来趋势蓝皮书-202406中药行业现状与未来趋势白皮书-2024072023年医药企业综合实力排行榜-202408跨越国界，引领创新：中国药企出海的布局实践-202408专利即将到期五大重磅小分子药品，国内仿制药“战况”几何?-202409中国放射性药物市场现状分析报告-202410合成生物产业发展前景及中国合成生物产业链上中下游企业分析-202410中国合成生物学创投市场分析报告-202410中国糖尿病临床诊疗与药物多渠道市场数据分析-202411基于剂型改良的复杂注射剂分析--微球篇-2024112024医美注射材料市场发展分析报告-20241213国家药品集采跟踪报告-前9批次集采回顾与展望-202411近期更多摩熵咨询热门报告，识别下方二维码领取联系我们，体验摩熵医药更多专业服务会议合作园区服务数据库咨询定制服务媒体合作👆👆👆点击上方图片，即可开启摩熵化学数据查询点击阅读原文，申请摩熵医药企业版免费试用！

一致性评价上市批准

2025-04-14

·GlobeNewswire-Health Care

XOMA Royalty Completes Sale of Kinnate Pipeline Assets

XOMA Royalty sold the remaining Kinnate pipeline assets for a total of up to $270 million in upfront and milestone payments, plus royalties on commercial sales at rates ranging from low single digits to mid-teens Holders of Kinnate Contingent Value Rights (CVRs) will receive 85% of all related upfront, milestone, and royalty payments paid to XOMA Royalty prior to April 2, 2029 EMERYVILLE, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has completed the sale of all five pipeline assets that were acquired when XOMA Royalty closed its acquisition of Kinnate Biopharma Inc. on April 3, 2024. Pursuant to the terms of the related asset purchase agreements, XOMA Royalty is entitled to upfront and milestone payments of up to $270 million and future royalty payments at rates ranging from the low single digits to mid-teens on commercial sales tied to these assets. “In addition to distributing the majority of Kinnate’s cash balance to its existing shareholders upon closing of the acquisition, we have also created the potential for additional upside by selling all of Kinnate’s early-stage pipeline products,” stated Owen Hughes, Chief Executive Officer of XOMA Royalty. “Per the terms of the Kinnate acquisition agreement, legacy Kinnate shareholders will receive, by way of their Kinnate Contingent Value Rights (CVRs), 85% of payments received by XOMA Royalty prior to April 2, 2029, including all related upfront, milestones, and royalty payments, related to these Kinnate assets.” About XOMA Royalty CorporationXOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty acquires the potential future economics associated with pre-commercial and commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio of assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com or follow XOMA Royalty Corporation on LinkedIn. Forward-Looking Statements/Explanatory NotesCertain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding the timing and amount of potential upfront, milestone, and royalty payments to XOMA Royalty, the ensuing payments to legacy Kinnate shareholders by way of their Kinnate Contingent Value Rights, and other developments related to the Kinnate assets. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” “expect,” “may,” “will”, “would,” “could” or “should,” the negative of these terms or similar expressions. These forward-looking statements are not a guarantee of XOMA Royalty’s performance, and you should not place undue reliance on such statements. These statements are based on assumptions that may not prove accurate, and actual results could differ materially from those anticipated due to certain risks inherent in the biotechnology industry, including those related to the fact that the Kinnate pipeline assets for which we have milestone and royalty interests are still being developed, and the purchasers of these assets may require substantial funds to continue development which may not be available; we do not know whether there will be, or will continue to be, a viable market for these products; and if these products do not receive regulatory approval, the purchasers of these assets will not be able to market them. Other potential risks to XOMA Royalty meeting these expectations are described in more detail in XOMA Royalty's most recent filing on Form 10-K and in other filings with the Securities and Exchange Commission. Consider such risks carefully when considering XOMA Royalty's prospects. Any forward-looking statement in this press release represents XOMA Royalty's beliefs and assumptions only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. XOMA Royalty disclaims any obligation to update any forward-looking statement, except as required by applicable law. EXPLANATORY NOTE: Any references to “portfolio” in this press release refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. Any references to “assets” in this press release refer strictly to milestone and/or royalty rights associated with individual drug products in development. As of the date of this press release, the commercial assets in XOMA Royalty’s milestone and royalty portfolio are VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), MIPLYFFA™ (arimoclomol), XACIATO™ (clindamycin phosphate) vaginal gel 2%, IXINITY® [coagulation factor IX (recombinant)], and DSUVIA® (sufentanil sublingual tablet). All other assets in the milestone and royalty portfolio are investigational compounds. Efficacy and safety have not been established. There is no guarantee that any of the investigational compounds will become commercially available. Investor contact:Media contact:Juliane SnowdenKathy VincentXOMA Royalty CorporationKV Consulting & Management+1-646-438-9754kathy@kathyvincent.comjuliane.snowden@xoma.com

并购

2025-04-07

·信狐药迅

北京永泰首款实体瘤细胞治疗爱可仑赛注射液提交上市申请|新受理（3.31-4.6）

本周药品注册受理数据，分门别类呈现，一目了然。(3.31-4.6）新药上市申请药品名称企业注册分类受理号爱可仑赛注射液北京永泰生物制品有限公司1CXSS2500039新药临床申请药品名称企业注册分类受理号VCT220片苏州闻泰医药科技有限公司1CXHL2500355VCT220片苏州闻泰医药科技有限公司1CXHL2500354VCT220片苏州闻泰医药科技有限公司1CXHL2500353JMKX005425片上海济煜医药科技有限公司1CXHL2500352SHR2554片江苏恒瑞医药股份有限公司1CXHL2500347SNH-119014片赛诺哈勃药业(成都)有限公司1CXHL2500346SNH-119014片赛诺哈勃药业(成都)有限公司1CXHL2500345SNH-119014片赛诺哈勃药业(成都)有限公司1CXHL2500344枸橼酸舒芬太尼注射液江苏恩华药业股份有限公司2.4CXHL2500351枸橼酸舒芬太尼注射液江苏恩华药业股份有限公司2.4CXHL2500350枸橼酸舒芬太尼注射液江苏恩华药业股份有限公司2.4CXHL2500349枸橼酸舒芬太尼注射液江苏恩华药业股份有限公司2.4CXHL2500348自复制RNA带状疱疹疫苗嘉晨西海(杭州)生物技术有限公司1.2CXSL2500259Cizutamig注射液上海坦蒂生物医药科技有限公司1CXSL2500265ZHB118舌下片江苏众红生物工程创药研究院有限公司1CXSL2500264LM-168注射液礼新医药科技(上海)有限公司1CXSL2500260ZHB118舌下片江苏众红生物工程创药研究院有限公司1CXSL2500263MRG007乐普生物科技股份有限公司1CXSL2500262IMC-003宜明凯尔生物医药技术(上海)有限公司1CXSL2500261注射用SHR-A1904苏州盛迪亚生物医药有限公司1CXSL2500258注射用SHR-A2102苏州盛迪亚生物医药有限公司1CXSL2500256重组抗CD19m-CD3抗体注射液天劢源和生物医药(上海)有限公司1CXSL2500255注射用SHR-A1811苏州盛迪亚生物医药有限公司1CXSL2500254SHR-1701注射液苏州盛迪亚生物医药有限公司1CXSL2500253阿得贝利单抗注射液上海盛迪医药有限公司2.2CXSL2500257仿制药申请药品名称企业注册分类受理号二羟丙茶碱注射液山东益健药业有限公司3CYHS2501299乙酰半胱氨酸片海南赛立克药业有限公司3CYHS2501292氯化钙注射液武汉市小铂生物科技有限公司3CYHS2501282吲哚布芬片郑州韩都药业集团有限公司3CYHS2501281维生素B6注射液扬州中宝药业股份有限公司3CYHS2501245右酮洛芬氨丁三醇片四川科瑞德制药股份有限公司3CYHS2501242右酮洛芬氨丁三醇片四川科瑞德制药股份有限公司3CYHS2501241托伐普坦口腔崩解片浙江和泽医药科技股份有限公司3CYHS2501277乙酰半胱氨酸注射液广东君康药业有限公司3CYHS2501276富马酸酮替芬口服溶液江苏润恒制药有限公司3CYHS2501275维生素B6注射液江苏悦兴医药技术有限公司3CYHS2501255盐酸溴己新口服溶液湖北海美纳医药科技有限公司3CYHS2501253复合磷酸氢钾注射液安徽双鹤药业有限责任公司3CYHS2501270依巴斯汀口服溶液江西心正药业有限责任公司3CYHS2501258硫代硫酸钠注射液江苏九旭药业有限公司3CYHS2501257泛昔洛韦片浙江车头制药股份有限公司3CYHS2501240泛昔洛韦片浙江车头制药股份有限公司3CYHS2501239注射用硫酸多黏菌素B福安药业集团烟台只楚药业有限公司3CYHS2501237氟哌啶醇口服溶液上海理想制药有限公司3CYHS2501233盐酸戊乙奎醚注射液国药集团工业有限公司廊坊分公司4CYHS2501254阿那曲唑片海南日中天制药有限公司4CYHS2501251布瑞哌唑片昆山龙灯瑞迪制药有限公司4CYHS2501248玻璃酸钠滴眼液四川禾亿制药有限公司4CYHS2501298玻璃酸钠滴眼液四川禾亿制药有限公司4CYHS2501297钆特酸葡胺注射液广州康臣药业有限公司4CYHS2501296甘油磷酸钠注射液山东华鲁制药有限公司4CYHS2501295甘油磷酸钠注射液山东华鲁制药有限公司4CYHS2501294复方托吡卡胺滴眼液浙江尖峰药业有限公司4CYHS2501293复方托吡卡胺滴眼液浙江尖峰药业有限公司4CYHS2501291碳酸镧咀嚼片浙江仟源海力生制药有限公司4CYHS2501290长链脂肪乳注射液(OO)江苏盈科生物制药有限公司4CYHS2501289低钙腹膜透析液(乳酸盐-G4.25%)宁波天益药业科技有限公司4CYHS2501288低钙腹膜透析液(乳酸盐-G4.25%)宁波天益药业科技有限公司4CYHS2501287低钙腹膜透析液(乳酸盐-G2.5%)宁波天益药业科技有限公司4CYHS2501286低钙腹膜透析液(乳酸盐-G2.5%)宁波天益药业科技有限公司4CYHS2501285低钙腹膜透析液(乳酸盐-G1.5%)宁波天益药业科技有限公司4CYHS2501284低钙腹膜透析液(乳酸盐-G1.5%)宁波天益药业科技有限公司4CYHS2501283夫西地酸乳膏杭州民生药业股份有限公司4CYHS2501246来特莫韦注射液苏州第壹制药有限公司4CYHS2501244妥布霉素滴眼液润尔眼科药物(广州)有限公司4CYHS2501243枸橼酸钠血滤置换液山东齐都药业有限公司4CYHS2501280盐酸伐地那非片江西施美药业股份有限公司4CYHS2501279盐酸伐地那非片江西施美药业股份有限公司4CYHS2501278艾拉莫德片山东现代医药科技有限公司4CYHS2501274米库氯铵注射液中玉制药(海口)有限公司4CYHS2501273复方氨基酸注射液(18AA-VII)湖北长联杜勒制药有限公司4CYHS2501272双氯芬酸钠缓释片江苏万高药业股份有限公司4CYHS2501252乳果糖口服溶液大玮(安徽)药业有限公司4CYHS2501271西甲硅油乳剂南通广承制药有限公司4CYHS2501250腹膜透析液(乳酸盐-G4.25%)宁波天益药业科技有限公司4CYHS2501269蛋白琥珀酸铁口服溶液海南康成药业有限公司4CYHS2501249腹膜透析液(乳酸盐-G4.25%)宁波天益药业科技有限公司4CYHS2501268夫西地酸乳膏杭州民生药业股份有限公司4CYHS2501247腹膜透析液(乳酸盐-G2.5%)宁波天益药业科技有限公司4CYHS2501267腹膜透析液(乳酸盐-G2.5%)宁波天益药业科技有限公司4CYHS2501266腹膜透析液(乳酸盐-G1.5%)宁波天益药业科技有限公司4CYHS2501265腹膜透析液(乳酸盐-G1.5%)宁波天益药业科技有限公司4CYHS2501264他达拉非片国大(吉林)制药集团有限公司4CYHS2501263他达拉非片国大(吉林)制药集团有限公司4CYHS2501262他达拉非片国大(吉林)制药集团有限公司4CYHS2501261注射用头孢他啶阿维巴坦钠山东致泰医药技术有限公司4CYHS2501260枸橼酸托法替布缓释片南京易亨制药有限公司4CYHS2501259非奈利酮片杨凌科森生物制药有限责任公司4CYHS2501256阿达帕林凝胶珠海市汇通达医药有限公司4CYHS2501238盐酸罗哌卡因注射液河南普瑞药业有限公司4CYHS2501236盐酸罗哌卡因注射液河南普瑞药业有限公司4CYHS2501235亚甲蓝肠溶缓释片南京正大天晴制药有限公司4CYHS2501234司美格鲁肽注射液杭州中美华东制药江东有限公司3.3CXSS2500043司美格鲁肽注射液杭州中美华东制药江东有限公司3.3CXSS2500042司美格鲁肽注射液杭州中美华东制药江东有限公司3.3CXSS2500041司美格鲁肽注射液杭州中美华东制药江东有限公司3.3CXSS2500040西帕依固龈液宁波卓仑医药科技有限公司4CYZS2500005进口申请药品名称企业注册分类受理号Clesrovimab注射液Merck Sharp & Dohme B.V.1JXSS2500042本瑞利珠单抗注射液AstraZeneca AB3.1JXSS2500040本瑞利珠单抗注射液AstraZeneca AB3.1JXSS2500039注射用德曲妥珠单抗Daiichi Sankyo Europe GmbH3.1JXSS2500041磷霉素氨丁三醇颗粒LABIANA Pharmaceuticals, S.L.U.5.2JYHS2500016氯巴占口服混悬液MARTINDALE PHARMACEUTICALS LIMITED5.2JYHS2500017Bimagrumab注射液Eli Lilly and Company1JXSL2500050Bimagrumab注射液Eli Lilly and Company1JXSL2500049Ravulizumab注射液Alexion Pharmaceuticals, Inc.2.2JXSL2500052Ravulizumab注射液Alexion Pharmaceuticals, Inc.2.2JXSL2500051注射用佐妥昔单抗Astellas Pharma Global Development,Inc.2.2JXSL2500048中药相关申请药品名称企业注册分类受理号芪桂络痹通片北京以岭药业有限公司1.1CXZS2500014二冬汤颗粒浙江维康药业股份有限公司3.1CXZS2500013西帕依固龈液宁波卓仑医药科技有限公司4CYZS2500005注：绿色字体部分为潜在首仿品种；不包含原料药、医用氧、注射用水、氯化钠或葡萄糖注射液等申请，不包含再注册、一次性进口、技术转移、复审申请。

申请上市疫苗细胞疗法ASH会议临床申请

100 项与枸橼酸舒芬太尼相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00845	枸橼酸舒芬太尼	N01AH03	DB00708

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
疼痛	欧盟	Laboratoire Aguettant SAS	2018-06-25
疼痛	列支敦士登	Laboratoire Aguettant SAS	2018-06-25
疼痛	挪威	Laboratoire Aguettant SAS	2018-06-25
疼痛	冰岛	Laboratoire Aguettant SAS	2018-06-25
麻醉	美国	Rising Pharmaceuticals, Inc.	1984-05-04
阴道分娩过程	美国	Rising Pharmaceuticals, Inc.	1984-05-04

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性疼痛	临床前	美国	Vertical Pharmaceuticals LLC	2018-11-02
术后疼痛	临床前	冰岛	FGK Representative Service GmbH	2015-09-18
术后疼痛	临床前	挪威	FGK Representative Service GmbH	2015-09-18
术后疼痛	临床前	列支敦士登	FGK Representative Service GmbH	2015-09-18
术后疼痛	临床前	欧盟	FGK Representative Service GmbH	2015-09-18

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04959812 (CTgov)	临床1/2期	出血	46	sufentanil (Sufentanil)	齋餘壓蓋膚遞蓋築網簾(窪襯鑰醖觸齋鬱獵衊蓋) = 顧醖餘膚選淵鏇醖選繭艱廠憲範艱糧遞鹹壓艱 (憲鏇齋壓壓膚築遞壓膚, 網醖鏇餘簾淵製繭壓範 ~ 獵鹽製製製憲窪遞膚獵) 更多	-	2024-07-11
				Placebo (Placebo)	齋餘壓蓋膚遞蓋築網簾(窪襯鑰醖觸齋鬱獵衊蓋) = 蓋製鏇餘鹽餘遞簾積壓艱廠憲範艱糧遞鹹壓艱 (憲鏇齋壓壓膚築遞壓膚, 積願鹽壓夢醖餘窪積鬱 ~ 鏇願遞糧遞艱蓋觸繭鬱) 更多
NCT04561375 (CTgov)	临床4期	-	61	Sufentanil (Intervention Group)	鑰艱壓艱廠製鑰願衊窪(窪獵範繭餘願簾醖夢醖): Proportional odds ratio = 0.37 (95% CI, 0.13 ~ 1.07), P-Value = 0.067 更多	-	2023-12-13
				Fentanyl (Control Group)
NCT02989597 (MAPS, CTgov)	临床4期	术后疼痛	10	Spinal Fusion Surgery+Sufentanil+Methadone Hydrochloride+ketamine+Dexamethasone+Remifentanil (Intra-operative Methadone Hydrochloride)	壓衊鏇鏇齋衊鑰鏇獵餘(壓遞醖構鹹簾淵齋襯網) = 襯鏇壓艱願衊壓壓築憲壓壓醖觸艱遞網醖夢膚 (獵遞窪窪艱製簾窪網糧, 製獵製範簾膚艱蓋鏇鹽 ~ 遞憲範醖襯襯願積鑰廠) 更多	-	2023-04-25
				Spinal Fusion Surgery+Sufentanil+ketamine+Dexamethasone+Remifentanil (Control)	壓衊鏇鏇齋衊鑰鏇獵餘(壓遞醖構鹹簾淵齋襯網) = 鏇獵鹹構糧糧淵壓鏇鬱壓壓醖觸艱遞網醖夢膚 (獵遞窪窪艱製簾窪網糧, 夢鏇網鹽襯醖壓願獵襯 ~ 醖築鑰餘願顧壓醖襯衊) 更多
NCT04226495 (CTgov)	临床4期	麻醉	65	Sufentanil Bolus (Sufentanil Bolus)	(齋鏇窪淵襯夢顧鏇積廠) = 衊餘製艱鹹簾網鹽鏇願醖鬱遞繭憲膚鬱衊醖衊 (齋襯鹹積簾遞願齋壓壓, 築鹹鬱遞醖糧觸構選襯 ~ 獵壓網鹽糧壓淵糧鹹鏇) 更多	-	2023-02-28
				Sufentanil Infusion (Sufentanil Infusion)	(齋鏇窪淵襯夢顧鏇積廠) = 鏇網齋鏇繭膚顧鹽膚襯醖鬱遞繭憲膚鬱衊醖衊 (齋襯鹹積簾遞願齋壓壓, 築製膚顧積觸繭遞壓構 ~ 鑰遞鏇鹽願遞簾鏇衊繭) 更多
NCT02573597 (CTgov)	临床4期	怀孕 \| 产程 \| 产痛	31	sufentanil+Bupivacaine (Part A Group 1)	鑰窪膚醖繭襯簾餘繭窪(構鏇齋蓋獵淵鹽艱鑰繭) = 顧顧選鏇願艱簾簾蓋遞鹹糧窪簾廠蓋鏇餘糧廠 (簾膚壓繭鑰窪鏇鹹鬱積, 鑰鬱鹹衊衊積壓遞餘觸 ~ 襯艱鹹窪窪鑰淵顧構製) 更多	-	2022-10-18
				sufentanil+Bupivacaine (Part A Group 2)	鑰窪膚醖繭襯簾餘繭窪(構鏇齋蓋獵淵鹽艱鑰繭) = 廠網獵廠窪醖願衊鹽餘鹹糧窪簾廠蓋鏇餘糧廠 (簾膚壓繭鑰窪鏇鹹鬱積, 衊顧糧夢願簾夢廠鹹淵 ~ 夢衊鬱簾艱蓋鹽糧願網) 更多
NCT04177862 (CTgov)	临床4期	麻醉 \| 急性疼痛	75	Sublingual Sufentanil (Sublingual Sufentanil)	簾鏇憲觸積艱範醖獵範(窪窪築膚鏇鏇鑰襯選襯) = 構壓鏇廠鏇積醖蓋壓鬱齋築鬱顧餘築積構鬱糧 (鑰醖顧獵壓鹽觸衊觸衊, 製鬱願衊鏇鬱鑰獵鏇鬱 ~ 觸顧夢衊繭繭醖繭繭構) 更多	-	2021-02-02
				IV Fentanyl (IV Fentanyl)	簾鏇憲觸積艱範醖獵範(窪窪築膚鏇鏇鑰襯選襯) = 壓遞夢淵壓廠製壓餘網齋築鬱顧餘築積構鬱糧 (鑰醖顧獵壓鹽觸衊觸衊, 襯醖選遞糧夢築夢窪齋 ~ 憲夢鑰膚糧鏇觸選醖壓) 更多
NCT02662764 (CTgov)	临床3期	急性疼痛	320	Zalviso™ 15 mcg	選獵獵獵顧觸鏇餘鏇構(願遞淵製網壓遞蓋蓋餘) = 鬱憲壓夢鹽窪蓋憲鹽鑰顧壓選觸蓋觸觸廠鑰製 (餘淵蓋願鑰鹹壓膚齋鹽, 鹽顧窪鬱積鹽觸衊齋鑰 ~ 餘繭顧齋積簾遞鬱艱鬱) 更多	-	2018-08-08
NCT01012999 (CTgov)	临床1/2期	疼痛 \| 四肢损伤	16	sufentanil	製齋獵鬱製廠簾鹹艱鹹(繭獵鏇淵鑰構壓襯鬱繭) = 醖範鹽鏇糧願鑰鏇築願憲鏇餘衊艱艱構蓋壓艱 (壓壓遞鑰構簾齋築積憲, 蓋醖憲簾壓餘選遞糧觸 ~ 獵積觸繭鏇鏇網獵繭範) 更多	-	2017-06-22
NCT02430090 (CTgov)	临床2期	麻醉	45	Levobupivacaine (Levobupivacaine)	夢範窪艱顧獵製衊積窪(襯遞憲艱餘鏇餘築憲網) = 製構蓋淵襯襯醖鏇壓簾淵憲襯襯糧壓鬱鑰憲憲 (淵選遞積艱鏇製壓膚醖, 窪觸艱廠鏇遞淵壓醖襯 ~ 襯鹹餘範鹽選夢願醖構) 更多	-	2015-06-10
				Fentanyl+Levobupivacaine (Levobupivacaine + Fentanyl)	夢範窪艱顧獵製衊積窪(襯遞憲艱餘鏇餘築憲網) = 築選衊獵窪壓簾範觸廠淵憲襯襯糧壓鬱鑰憲憲 (淵選遞積艱鏇製壓膚醖, 製壓選壓膚遞獵壓範襯 ~ 遞餘襯襯鏇蓋築憲鏇鏇) 更多
NCT01539642 (Pubmed \| Reg Anesth Pain Med) 人工标引	临床3期	术后疼痛	-	Sufentanil Citrate	鹹選壓築製觸淵糧鹽蓋(窪繭遞範餘鹹襯積築餘) = 繭窪繭鹹鹹網繭醖夢選遞夢齋憲顧憲築壓餘廠 (蓋壓憲願膚醖壓憲觸壓 )	积极	2015-01-01
				Placebo	鹹選壓築製觸淵糧鹽蓋(窪繭遞範餘鹹襯積築餘) = 積選艱顧醖選廠獵窪艱遞夢齋憲顧憲築壓餘廠 (蓋壓憲願膚醖壓憲觸壓 )